Tesamorelin vs Sermorelin: Classification Differences Explained
A reference breakdown of tesamorelin vs sermorelin classification differences, covering peptide structure, molecular weight, and how listings label each compound.
Reviewed by Yuki Tanaka, PhD, molecular biologist ·
Yuki Tanaka, PhD is a molecular biologist with a doctorate from Osaka University and postdoctoral training at Stanford School of Medicine, specializing in growth hormone axis biology, GHRH receptor signaling, and synthetic peptide analog mechanisms.
Tesamorelin and sermorelin are both classified as growth hormone-releasing hormone (GHRH) analogs, but the tesamorelin vs sermorelin classification differences go deeper than a shared category label. The two compounds differ in amino acid sequence length, structural modification, and how regulatory and reference literature categorize them within the broader GHRH-analog family. Understanding these distinctions matters for anyone reading vendor listings, comparing certificates of analysis, or trying to make sense of why two “GHRH analog” products are priced and documented so differently.
What “GHRH Analog” Actually Means
Growth hormone-releasing hormone is a naturally occurring 44-amino-acid peptide. Most synthetic analogs used in research are truncated or modified fragments that retain the biologically active portion of that sequence while altering stability or half-life. Both tesamorelin and sermorelin fall under this umbrella term, which is why listings sometimes group them together in the same product category. But “GHRH analog” is a functional classification, not a structural one — it describes a mechanism of action, not a specific molecule. Two peptides can share this classification while differing substantially in sequence length, molecular weight, and formulation stability.
Structural Classification Differences
Sermorelin is typically described as a GHRH(1-29) fragment — the first 29 amino acids of the native 44-amino-acid GHRH sequence. This is the shortest fragment generally recognized as retaining GHRH receptor activity, which is why sermorelin is often classified as the “core” or “minimal” GHRH analog in reference literature.
Tesamorelin is built on a similar GHRH(1-44) backbone but includes a modification at the N-terminus: a trans-3-hexenoic acid group attached to the first amino acid. This structural addition is why tesamorelin is sometimes classified separately as a “stabilized” or “modified” GHRH analog rather than a simple fragment. The modification is documented as increasing resistance to enzymatic degradation, which changes the compound’s classification profile even though the receptor-binding mechanism is related to sermorelin’s.
| Attribute | Tesamorelin | Sermorelin |
|---|---|---|
| Base sequence | GHRH(1-44) analog | GHRH(1-29) fragment |
| Structural modification | N-terminal trans-3-hexenoic acid group | None (unmodified fragment) |
| Common classification label | Modified/stabilized GHRH analog | Fragment GHRH analog |
| Typical listed molecular weight | Higher (larger backbone plus modification) | Lower (shorter fragment) |
| Common vial sizing seen in listings | 2mg, 5mg, 10mg | 2mg, 5mg |
Why Molecular Weight Shows Up in Classification
Vendor listings and COAs frequently cite molecular weight as a way to distinguish these two compounds at a glance. Because tesamorelin retains a longer backbone and carries an added acyl group, its listed molecular weight is meaningfully higher than sermorelin’s. This isn’t just a trivia point — molecular weight is one of the values a COA’s mass spectrometry section should confirm, and a mismatch between the stated compound and its expected molecular weight range is a red flag on any documentation.
Reconstitution math is unaffected by which classification a peptide falls under, but it’s still worth walking through a concrete example. If a 5mg vial of either compound is reconstituted with 2mL of bacteriostatic water, the resulting concentration is:
5mg ÷ 2mL = 2.5mg/mL, or 2500mcg/mL
On a U-100 insulin syringe, where 1mL equals 100 units, that concentration means each unit drawn corresponds to 25mcg (2500mcg ÷ 100 units = 25mcg per unit). This calculation is identical regardless of which GHRH analog is in the vial — classification differences affect the molecule’s structure and stability profile, not the arithmetic of dilution. Readers who want to verify vial-specific math independently can cross-check figures using a tool like peptcalc.com.
How Listings Use These Classifications Inconsistently
One source of confusion in the peptide reference space is that not all vendors apply classification terms consistently. Some listings describe sermorelin simply as “GHRH,” omitting the fragment designation entirely, while others are more precise and note the (1-29) sequence length. Tesamorelin listings are somewhat more standardized because the compound has a defined pharmaceutical history, but even here, terms like “modified GHRH” and “stabilized GHRH analog” are used interchangeably without a single agreed-upon label.
This inconsistency is why cross-referencing a listing against its COA matters more than trusting the classification language in the product title alone. A COA that identifies the correct molecular weight, sequence, and purity percentage tells a reader more than a marketing label does. Buyers comparing documentation across multiple vendors are better served by sourcing tesamorelin from a this tesamorelin listing than by relying on how a listing categorizes the compound in its title.
Practical Implications of the Classification Difference
Because tesamorelin and sermorelin are structurally distinct despite their shared GHRH-analog classification, they are not interchangeable in reference material, dosing charts, or reconstitution guides. A calculation, storage note, or stability guideline written for one should not be assumed to apply to the other without checking the specific compound’s documentation. Vial sizing conventions also differ slightly across listings — tesamorelin is more commonly seen in 10mg vials in addition to 2mg and 5mg, while sermorelin listings more often top out at 5mg. Readers comparing costs or specs across compounds within the same research cluster may also want to see cost-focused breakdowns, such as those available across peer tesamorelin listing catalogs, alongside classification details.
Summary
Tesamorelin and sermorelin share a broad classification as GHRH analogs, but the tesamorelin vs sermorelin classification differences are meaningful once you look past that shared label. Sermorelin is a shorter, unmodified GHRH(1-29) fragment, while tesamorelin carries a longer backbone with an added N-terminal group that changes its molecular weight and stability classification. Reading COAs for molecular weight and sequence data, rather than relying on how a listing titles the product, is the most reliable way to confirm which compound is actually in a given vial.
A note on how to read this
This article is written for research and educational reference. The materials described are sold for laboratory research and are not for human consumption. Nothing here is dosing guidance, a prescription, or a clinical recommendation.